Announced · Sweden · Pharma and biotech
ANI Pharmaceuticals to acquire Egetis Therapeutics.
ANI Pharmaceuticals, a Nasdaq-listed pharmaceutical company based in Princeton, New Jersey, announced on 5 November 2026 a recommended public cash offer of SEK 11.25 per share for Egetis Therapeutics, a Nasdaq Stockholm-listed rare disease company headquartered in Stockholm. Shareholders holding about 42.2 percent of the shares have undertaken to accept; the acceptance period is expected to run from about 20 November to 18 December 2026. It was announced on 5 November 2026 and had not been signed by 5 November 2026.
Announced 5 November 2026
- Buyer
- ANI Pharmaceuticals, Inc. ·Princeton, United States
- Target
- Egetis Therapeutics AB (publ) ·Stockholm, Sweden
- Type
- Acquisition
- Announced
- 5 November 2026
- Value
- about SEK 5,304 million (SEK 11.25 per share)
- People
- Not stated in the release
- Last checked
- 5 November 2026
The people side in Sweden
- Where the deal needs EU merger clearance, the buyer may not implement it before clearance. EU Merger Regulation (Council Regulation (EC) No 139/2004), article 7
- In an asset deal, staff move on their existing terms, and the transfer alone is no ground for dismissal. Acquired Rights Directive (Council Directive 2001/23/EC), articles 3 and 4
- In an asset or business transfer, seller and buyer each inform their staff representatives in good time of the date, reasons, implications and planned measures, and consult on those measures. Acquired Rights Directive (Council Directive 2001/23/EC), article 7
- Depending on the country, undertakings with 50 or more employees, or establishments with 20 or more, inform and consult employee representatives on decisions likely to change work organisation or contractual relations substantially. Information and Consultation Directive (Directive 2002/14/EC), articles 3 and 4
Related deals
- 23 Sep
Arcturus Therapeutics Holdings Inc.to
myNEO Therapeuticsdeal page: Arcturus Therapeutics acquires myNEOCompleted
not statedSigningDay 100 - 9 Sep
Revvity, Inc.to
Human Cell Designdeal page: Revvity agrees to acquire Human Cell DesignSigned
not statedSigningDay 100 - 3 Sep
Resonant Clinical Solutionsto
Creapharm Bioservicesdeal page: Resonant Clinical Solutions acquires Creapharm BioservicesCompleted
not statedSigningDay 100 - 1 Jun
Ryan, LLCto
Svalner Atlas Advisorsdeal page: Ryan acquires Svalner Atlas AdvisorsCompleted
about 500SigningDay 100